Mumbai, India and Warren, New Jersey, USA, September 3, 2026
Cipla Limited, through its wholly owned subsidiary InvaGen Pharmaceuticals Inc., has announced an exclusive strategic partnership with Qilu Pharmaceutical Co., Ltd. for the licensing and supply of QL2107, a biosimilar to Keytruda® (pembrolizumab), for the United States market. Under the agreement, Qilu will lead the product’s development, regulatory registration and supply, while Cipla USA will be responsible for commercialization in the U.S. The collaboration expands Cipla’s growing biosimilar and oncology portfolio and represents another step toward increasing access to advanced biologic treatments for patients with cancer.
Cipla Expands U.S. Biosimilar Oncology Strategy
The partnership adds QL2107, a pembrolizumab biosimilar candidate, to Cipla’s emerging U.S. biosimilar portfolio. Pembrolizumab is the active ingredient in Keytruda, a widely used PD-1-targeting immunotherapy, making the development and commercialization of biosimilar versions strategically important within the oncology market. Through the agreement, Qilu will utilize its capabilities in biopharmaceutical development and manufacturing, while Cipla will leverage its established U.S. commercial infrastructure to support the potential introduction of QL2107. The companies said the collaboration reflects their shared objective of improving access to high-quality biologic therapies while addressing the growing global burden of cancer. For Cipla, the agreement also reinforces its stated ambition to develop a stronger oncology-focused portfolio and expand its presence in the U.S. biosimilars segment. Achin Gupta, Managing Director and Global Chief Executive Officer of Cipla, highlighted the company’s confidence in the long-term potential of biosimilars, while emphasizing the combination of Qilu’s development capabilities with Cipla’s commercial reach. The partnership therefore brings together complementary strengths across R&D, manufacturing, regulatory activities and commercialization, potentially creating a broader platform for future biologic launches.
Qilu to Lead Development and Regulatory Activities
Under the terms announced by the companies, Qilu Pharmaceutical will be responsible for development, regulatory registration and supply of QL2107. Cipla USA will manage commercialization in the defined U.S. territory, subject to the necessary regulatory requirements. This division of responsibilities allows each company to focus on its established capabilities while creating a coordinated pathway for the potential launch of the biosimilar. The regulatory pathway remains an important milestone. QL2107 is not yet an FDA-approved product, and any U.S. launch will depend on obtaining the required regulatory authorization. Cipla’s North American leadership specifically described the product as one it aims to successfully launch subject to regulatory approval. This distinction is important as biosimilar development requires comprehensive analytical, pharmacokinetic, immunogenicity and clinical evidence demonstrating similarity to the reference biologic in accordance with regulatory requirements. For the pharmaceutical industry, the agreement highlights the increasing role of strategic licensing partnerships in expanding biosimilar pipelines. Instead of independently developing every asset, companies can combine specialized development and manufacturing expertise with established regional commercial networks, potentially accelerating access to competitive biologic therapies.
Advertisement
QL2107 Could Strengthen Affordable Cancer Care
The partnership comes as pharmaceutical companies continue to pursue opportunities to broaden access to biologic cancer treatments through biosimilar competition. By combining Qilu’s R&D and manufacturing strengths with Cipla’s U.S. commercial capabilities, the companies aim to establish a pathway for bringing a high-quality and potentially more affordable pembrolizumab biosimilar to American patients. Qilu General Manager Hanchang Zhang said the company has a growing biosimilar pipeline and views the collaboration with Cipla as an opportunity to combine its biopharmaceutical capabilities with Cipla’s U.S. market expertise. If QL2107 receives regulatory approval, the product could become an important addition to Cipla’s U.S. oncology strategy and contribute to the broader expansion of biosimilar treatment options. The agreement consequently represents more than a licensing and supply arrangement: it demonstrates how cross-border biopharmaceutical partnerships can connect development, manufacturing, regulatory expertise and commercial capabilities to support the next generation of biologic medicines.
Source: Cipla press release
